Mor Research Applications, a subsidiary of Clalit, Israel’s largest state-mandated health service organization, announced Tuesday it has agreed to join the Aspire Ventures Precision Medicine Fund and the Smart Health Innovation Lab (iLab) in an effort to develop and advance precision medicine technologies across the globe.
Mor Research Applications is the Technology Transfer Office of Clalit Health Services.
The collaboration is part of a strategic partnership agreement among Aspire, Penn Medicine Lancaster General Health (LG Health), Capital BlueCross, Clio Health, Clalit, and Mor.
Aspire Ventures partnered with Penn Medicine Lancaster General Health (LG Health) to launch the Aspire Ventures Precision Medicine Fund, a unique fund aimed at advancing precision medical technologies and practices through the leverage of AI and IoT. The goal is to deliver affordable, individualized solutions at a massive scale, the company says.
“Through a robust program of cross-border venture capital with US and Israel, the US market is being opened to the transformational technological force of the Start-up Nation. In return, worthy Israeli start-ups will benefit from unique commitments of U.S. health systems to provide contracts and reimbursement,” said Essam Abadir, a managing partner at Aspire Ventures.
The Smart Health Innovation Lab (iLab) finds and develops new approaches to healthcare that can be deployed in new markets by connecting healthcare startups with experts in the healthcare field. It was established by Aspire, LG Health, Capital BlueCross, and Clio Health.
“This new partnership not only helps us enter the U.S. market, but represents a joining of international forces to pursue solutions for the challenges conceived and developed by Clalit’s professionals. This marks global growth for all partners via collaboration in an established fund,” said MOR CEO Pini Ben-Elazar.